Clinical trial
Docetaxel and Erlotinib in Treating Patients With Advanced Non-Small Cell Lung…
NCT00390429 · University of California, Davis, Other · Completed
Key facts
| NCT number | NCT00390429 |
|---|---|
| Title | Docetaxel and Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer or Other Solid Tumors |
| Official title | Phase I/II Study of Docetaxel and OSI-774 (Erlotinib) in Solid Tumor Patients With an Emphasis on NSCLC Using Molecular Correlates as Potential Markers of Response |
| Lead sponsor | University of California, Davis, Other |
| Collaborators | National Cancer Institute (NCI) NIH Genentech, Inc. Industry Aventis Pharmaceuticals |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Lung Cancer, Unspecified Adult Solid Tumor, Protocol Specific |
| Intervention type | Drug |
| Interventions | docetaxel, erlotinib hydrochloride |
| Enrollment | 81 |
| Start date | Jul 1, 2002 |
| Primary completion | Aug 1, 2008 |
| Completion | Aug 1, 2012 |
| First posted | Oct 19, 2006 |
| Last update posted | Dec 6, 2018 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: